Vor Biopharma Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Vor Biopharma Inc. (VOR) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $107.30 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $107.30M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $109.80M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $113.40M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $82.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $107.30M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $109.80M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $113.40M 10-K · filed 2026-03-30 |
| 2025-09-30 | $82.30M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $66.30M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $11.60M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $8.00M 10-K · filed 2025-03-20 |
| 2024-09-30 | $9.30M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $11.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $14.00M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $14.00M 10-K · filed 2024-03-20 |
| 2023-09-30 | $17.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $19.20M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $19.90M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $16.20M 10-K · filed 2023-03-23 |
| 2022-09-30 | $16.80M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $17.30M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $20.90M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $13.10M 10-K · filed 2022-03-14 |
| 2021-09-30 | $14.00M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $14.10M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $13.90M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |